Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Connaught HSE, 1 Burlington Road DUBLIN 00000 |
Tel: | N/A |
Website: | https://www.alkermes.com |
IR: | See website |
Key People | ||
Richard F. Pops Chairman of the Board, Chief Executive Officer | Iain M. Brown Chief Financial Officer, Senior Vice President | Blair C. Jackson Chief Operating Officer, Executive Vice President |
David Joseph Gaffin Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary | Craig C. Hopkinson Executive Vice President, Research and Development and Chief Medical Officer | Michael J. Landine Senior Vice President - Corporate Development, Chief Risk Officer | C.Todd Nichols Senior Vice President, Chief Commercial Officer |
Business Overview |
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio. |
Financial Overview |
For the fiscal year ended 31 December 2023, Alkermes Plc revenues increased 50% to $1.66B. Net income before extraordinary items totaled $519.2M vs. loss of $33.2M. Revenues reflect Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA segment increase from $115.7M to $486.1M, LYBALVI segment increase of 100% to $191.9M, United States segment increase of 60% to $1.49B. Net Income reflects Interest Income increase from $7.6M to $30.9M (income). |
Employees: | 2,100 as of Feb 9, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,669M as of Dec 31, 2023 |
Annual revenue (TTM): | $1,663M as of Dec 31, 2023 |
EBITDA (TTM): | $495.05M as of Dec 31, 2023 |
Net annual income (TTM): | $519.16M as of Dec 31, 2023 |
Free cash flow (TTM): | $353.31M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 169,184,183 as of Mar 18, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |